The Spravato Clinician Guide: Supporting Patients with Curated Audio is a practical framework for helping patients feel safe, grounded, and emotionally supported during esketamine sessions using intentionally selected, lyric-free music. Because Spravato temporarily quiets the brain's language center, clinicians can improve tolerability and comfort by pairing the 2-hour monitoring window with sound engineered to work alongside the medicine's neurological effects.
Listening to Spravato, founded by conservatory-trained musician and Spravato patient Justin Page, develops these audio resources specifically for the clinical setting. Below, we translate the science of music-assisted care into steps your clinic can apply during induction, maintenance, and monitoring.
What Is the Spravato Clinician Guide: Supporting Patients with Curated Audio?
This guide is a clinician-facing approach to integrating curated audio into Spravato treatment. Rather than handing patients a random playlist or a guided meditation, it uses music selected to complement esketamine's dissociative and sedative effects -- no lyrics, no verbal cues, just sound designed to keep patients regulated.
Spravato received FDA approval on March 5, 2019, for treatment-resistant depression in adults in conjunction with an oral antidepressant, according to the American College of Clinical Pharmacology. In 2025, the FDA expanded that approval to allow Spravato as a standalone monotherapy for major depressive disorder, per UTHealth Houston's Department of Psychiatry -- widening the population of patients who may benefit from a thoughtful audio protocol.
Why Does Curated Audio Matter During Spravato Sessions?
The clinical case for music is not merely comforting -- it is measurable. Research published in 2024 on PubMed found that listening to music during intranasal esketamine therapy appears linked to reduced anxiety and lower blood pressure, with improved tolerance for higher doses. For clinicians managing dose escalation, that tolerability matters.
Sedation and dissociation are expected effects. According to the 2025 FDA prescribing label, 48% to 61% of Spravato-treated patients developed sedation, and 0.3% to 0.4% experienced loss of consciousness. Curated audio gives patients a steady anchor during these altered states, reducing the likelihood of agitation without pharmacological intervention.
Grounding
Steady, wordless sound provides a consistent focal point when language processing is impaired.
Autonomic regulation
Slower tempos support the lower blood pressure and reduced anxiety observed in the 2024 research.
Dose tolerance
Comfortable patients tolerate the standard induction doses of 56 mg or 84 mg more readily.
How Should Clinicians Match Audio to the Spravato Dosing Protocol?
The FDA-approved dosing protocol involves an induction phase (weeks 1-4) of twice-weekly doses of 56 mg or 84 mg, followed by a maintenance phase (weeks 5-8) of 56 or 84 mg once weekly, per the American College of Clinical Pharmacology. Audio strategy should evolve alongside this timeline.
Early sessions are unfamiliar. Choose slow, ambient, wordless music with minimal dynamic surprises. The goal is to reduce first-session anxiety while the patient learns what the medicine feels like.
Once a patient knows their response pattern, clinicians can offer a small selection of genre-based options. Consistency still matters -- patients often report that a familiar sonic environment shortens the emotional recovery curve after each session.
Patients may use a blanket, eye mask, or an immersive audio experience during their 2-hour monitoring period. Not every patient wants continuous sound; the guide treats deliberate silence as a valid, clinically supported choice.
What Should Clinicians Tell Patients Interested in Music-Assisted Spravato?
Framing matters. Explain that Spravato quiets the language center of the brain, which is exactly why lyric-free music helps -- words compete for the same neural resources the medicine is quieting. A short pre-session conversation sets expectations and builds trust.
Explain the "why"
Tell patients the music is chosen to work with the medicine, not to distract from it. Spravato quiets the language center of the brain -- lyric-free music helps because words compete for the same neural resources the medicine is quieting.
Set volume together
Let patients choose a comfortable level before dosing begins. Volume preference is personal and can shift across sessions as patients become more familiar with the dissociative state.
Offer opt-out
Make clear that silence is always available. Some patients find continuous sound grounding; others prefer quiet during integration. Both are valid.
Normalize the experience
Reassure patients that dissociation and drowsiness are expected and monitored. According to the 2025 FDA prescribing label, 48% to 61% of Spravato-treated patients developed sedation. Framing this as normal reduces pre-session anxiety.
Debrief briefly
A few post-session questions help refine the audio choice for next time. "How did the music feel?" is often enough to surface useful information for the next session record.
These conversation points reflect the practical, safety-forward framework in the book Listening to Spravato, released March 12, 2026, which provides clinicians a structured method for using music to enhance patient stability, emotional grounding, and therapeutic outcomes. You can explore the full Listening to Spravato curated playlists to build your clinic's audio library.
Access, Cost, and Why Comfort Supports Adherence
An estimated 21 million adults in the U.S. are living with major depressive disorder, according to Johnson & Johnson -- a large population for whom treatment retention is a real clinical challenge. Comfortable, well-supported sessions help patients stay in treatment through the full protocol.
Cost is often a patient's first question. Most commercially insured patients pay between $10 and $125 per Spravato session after meeting their deductible, with monthly out-of-pocket costs typically falling below $500, according to Healing Maps. Curated audio adds no drug cost and requires only headphones and a vetted playlist -- one of the lowest-friction quality-of-care improvements a clinic can adopt.
The efficacy data underscore why keeping patients engaged is worth the effort: in clinical trials, 22.5% of patients taking Spravato achieved remission compared with 7.6% of patients taking placebo after 4 weeks, per reporting from Renal & Urology News. A patient who dreads the sensory experience is less likely to complete the induction phase that drives those outcomes.
Building an Audio Protocol Into Your Clinical Workflow
Listening to Spravato, specializing in scientifically-informed music resources for esketamine treatment, recommends standardizing your audio approach so any staff member can support it consistently.
Curate, don't improvise
Keep 2-3 approved, lyric-free playlists rather than pulling from a general streaming service. Consistency across staff reduces variability in the patient experience.
Document preferences
Note each patient's chosen genre and volume in their session record. This allows any monitoring staff member to set up audio correctly without asking the patient to repeat themselves.
Train the whole team
Ensure monitoring staff know how to start, adjust, and stop audio without disrupting the patient. A brief protocol card at the monitoring station is sufficient.
Review quarterly
Refresh playlists based on patient feedback and new session tips. Patient preferences evolve across the induction and maintenance phases, and your audio library should too.
This is a small operational change with outsized impact on the patient experience -- and it costs nothing beyond a set of headphones and a curated library.
Frequently Asked Questions
Is there scientific evidence that music helps during Spravato treatment?
Yes. A 2024 study published on PubMed found that listening to music during intranasal esketamine therapy was associated with reduced anxiety and lower blood pressure, with improved tolerance for higher doses. The mechanism aligns with what we know about esketamine's effects on the default mode network: lyric-free music provides a steady, non-verbal anchor that supports autonomic regulation without re-engaging the language-processing regions the medicine is quieting.
Why should the music be lyric-free?
Spravato works in part by temporarily quieting the brain's default mode network -- the self-referential narrator that drives rumination and depression. Lyrics re-engage that network immediately, competing with the very neurological process the medicine is trying to facilitate. Lyric-free, instrumental music provides emotional support without verbal interference, allowing the dissociative state to deepen rather than pulling the patient back into language-based thinking.
Do patients have to listen to music the whole session?
No. Deliberate silence is a clinically valid choice. Some patients prefer music during onset and peak phases but want quiet during integration. Others prefer continuous sound throughout. The key is to make the choice intentional and to offer opt-out clearly before dosing begins. Document the patient's preference in their session record so any staff member can support it consistently.
How much does Spravato treatment cost with insurance?
Most commercially insured patients pay between $10 and $125 per Spravato session after meeting their deductible, with monthly out-of-pocket costs typically falling below $500, according to Healing Maps. Curated audio adds no drug cost -- it requires only headphones and a vetted playlist, making it one of the lowest-friction quality-of-care improvements a clinic can adopt.
Can Spravato be used without an oral antidepressant now?
Yes. Spravato originally received FDA approval in 2019 for treatment-resistant depression in adults in conjunction with an oral antidepressant. In 2025, the FDA expanded that approval to allow Spravato as a standalone monotherapy for major depressive disorder, per UTHealth Houston's Department of Psychiatry. This expansion widens the population of patients who may benefit from a thoughtful audio protocol.